1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Jiuzhitang Co., Ltd. Class A

Jiuzhitang Co., Ltd. Class A

SSZSE:000989
8.46
CNY
+0.08
(+0.95%)
6.65BMarket Cap
Oct 26Next Earn
Jiuzhitang Co., Ltd. Class A
SZSE:000989
(Shenzhen Stock Exchange)

Recent

price

8.46

P/E

ratio

- -

div

yld

3.56%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.3
3.37
3.01
3.56
1.51
1.65
3.08
4.37
3.67
3.78
4.24
4.43
3.54
3.46
2.79
2.63
- -
Revenue per Share
0.48
0.59
0.32
0.66
0.77
0.89
0.75
0.82
0.39
0.23
0.32
0.32
0.42
0.35
0.25
0.26
- -
Basic EPS, GAAP
0.46
0.07
-0.22
-0.65
0.56
0.55
0.62
0.03
0.33
0.83
0.63
0.19
0.47
0.04
0.15
0.46
- -
Free Cash Flow per Basic Share
0.35
0.35
0.34
0.17
0.08
0.19
0.35
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.3
Dividend per Share
4.03
4.23
4.28
4.5
4.1
4.36
4.76
5.18
4.94
4.59
4.51
4.57
4.65
4.62
4.38
4.35
4.3
Book Value per Share
3.71
3.82
3.88
4.11
3.9
3.84
4.26
4.65
4.44
4.1
3.97
4.04
4.16
4.15
3.83
3.53
3.49
Tangible Book Value per Share
340
341
347
340
527
529
869
869
863
842
840
855
856
856
850
846
846
Basic Weighted Avg Shares
1,122
1,150
1,042
1,212
798
872
2,674
3,797
3,162
3,184
3,560
3,784
3,033
2,961
2,371
2,229
- -
Sales/Revenue/Turnover
14.65
17.99
9.83
10.19
57.89
60.67
25.73
19.63
12.78
10.81
12.42
11.4
8.99
10.72
8.67
12.2
- -
Operating Margin (%)
36
26
24
23
45
43
98
94
106
99
108
163
148
127
121
125
- -
Depreciation Expense
163
202
112
225
403
471
652
712
336
192
272
271
358
297
216
223
- -
Net Income, GAAP
14.4
16.85
16.74
16.8
14.67
14.9
15.06
15.3
15.7
29.69
23.23
24.87
22.03
15.63
14.84
15.59
- -
Effective Tax Rate (%)
14.5
17.55
10.7
18.55
50.57
54.05
24.38
18.76
10.64
6.04
7.65
7.15
11.8
10.04
9.12
9.99
- -
Profit Margin (%)
910
918
790
765
608
1,783
2,203
2,211
2,033
1,684
1,616
1,597
1,636
1,630
1,721
1,629
1,672
Working Capital
1
1
1
1
1
1
1
- -
- -
- -
82
59
9
9
8
22
22
LT Debt
1,380
1,450
1,467
1,542
1,404
3,788
4,137
4,503
4,311
3,992
3,925
3,970
3,980
3,947
3,948
4,114
4,148
Total Equity
11.54
13.22
6.96
13.45
26.96
17.65
15.64
15.86
7.25
4.53
6.57
6.64
8.62
7.2
5.31
6.35
- -
Return on Invested Capital (%)
12.3
14.25
7.63
14.92
27.35
18.14
16.44
16.49
7.65
4.76
6.75
6.77
8.95
7.42
5.42
4.55
- -
Return on Capital (%)
12.34
14.27
7.65
14.95
27.4
18.15
16.45
16.49
7.65
4.64
6.89
6.86
9
7.5
5.61
5.96
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
62
70
40
LT Borrowings
12
12
11
LT Finance Leases
9
9
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
856
856
856
Market Capitalization
7,472
8,003
6,651

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,813
3,135
2,922
Cash, Cash Equivalents & STI
912
1,031
1,089
Accounts Receivable, Net
336
599
450
Inventories
950
840
850
Total Current Liabilities
1,184
1,304
1,250
Payables & Accruals
- -
- -
- -
ST Debt
62
70
40
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.95%
0.96%
4.2%
Free Cash Flow
146.59%
90.29%
204.82%
Net Income, GAAP
-1.59%
-1.92%
2.96%
Sales/Revenue/Turnover
20.28%
-8.36%
-5.99%
Total Cash Common Dividend
- -
-4.83%
-24.77%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,079
600
384
308
2,371
2025
806
459
- -
602
2,229
2026
973
659
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.07
0.04
-0.03
0.25
2025
0.14
0.03
- -
0.08
0.26
2026
0.19
0.1
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.4
2025
- -
- -
- -
- -
0.3
2026
- -
0.3
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiuzhitang Co., Ltd. (000989.SZ) engages primarily in the research, development, production and sales of traditional Chinese medicines, chemical drugs, biological products and health supplements in China. The company offers a broad portfolio of over-the-counter (OTC) drugs including Liuwei Dihuang Pills, Xiaoyao Pills, Weizhi Huang Pills, Qiju Dihuang Pills, Ejiao series products, Kidney and Tooth Supplement, Spleen and Qi Pills, Hair Growth Pills, Nuhua Purple Pearl Tablets, Xiaojin Pills, Guizhi Poria Pills, Laryngitis Pills and Gastric Ulcer Healing Tablets; prescription drugs such as Shuxuetong Injection, Blood Relieving Injections, Angong Niuhuang Pills, Tianma Gongteng Granules, Compound Lipid-lowering Tablets, Hematology and Pain Relief Capsules and Astragalus Red Dan yellowing granules; and comprehensive health products encompassing precious drinks, substitute teas, pastes, special meals and high-end health supplements. It operates through subsidiaries like Mudanjiang Youbo Pharmaceutical Co., Ltd. and maintains over 500 chain stores, alongside ventures into stem cells, innovative drugs, internet hospitals and pharmaceutical chains, serving domestic markets with a focus on cardiovascular, dermatology, digestive, gynecologic, respiratory and urinary systems. Founded in 1999 with roots tracing to Laojiuzhitang Pharmacy in 1650 and headquartered in Changsha, Hunan province, the company functions as a national key high-tech enterprise, innovative pilot entity and national enterprise technology center. In recent developments, Jiuzhitang agrees to acquire a 35% stake in Harbin Jixianglong Biotechnology Co., Ltd. for CNY 210 million and subscribes for additional shares to secure controlling ownership of 51.6667%, bolstering its stem cell and regenerative medicine capabilities; meanwhile, Heilongjiang Chenneng Gongda Venture Capital Co., Ltd. completes acquisition of an additional 6.25% stake in Jiuzhitang, elevating its holding to 24.04% as of early 2025.